

16.2.7 Adverse Event Listings (Each Participant)

Listing 10: Solicited Events – Systemic Symptoms

Listing 11: Solicited Events – Local Symptoms

Listing 12: Unsolicited Adverse Events

**Listing 10:
Solicited Events – Systemic Symptoms**

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00090	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Day 1	MA	36.5	Moderate	Moderate	Moderate	Mild	None	None
COV.00090	250 µg (18-55 years)	02	Day 2	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Mild	Mild	None
COV.00090	250 µg (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00090	250 µg (18-55 years)	02	Day 4	MA	36.3	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00090	250 µg (18-55 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00044	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	Mild	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00044	100 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00043	100 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 1	MA	36.4	None	None	None	None	None	Moderate
COV.00043	100 µg (18-55 years)	02	Day 2	MA	37.3	Mild	None	Moderate	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00043	100 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00051	100 µg (18-55 years)	01	Day 2	MA	36.9	None	None	Mild	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Mild	Moderate	Mild	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00051	100 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00051	100 µg (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Day 2	MA	38.1 (Mild)	Moderate	Moderate	Moderate	None	Moderate	None
COV.00049	100 µg (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00049	100 µg (18-55 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00049	100 µg (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 1	MA	37.3	None	Mild	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 2	MA	37.6	None	Mild	None	None	Mild	None
COV.00046	100 µg (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	01	Day 8	MA	37.4	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00046	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 1	MA	37.6	None	Mild	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 2	MA	37.6	None	Moderate	None	None	Mild	None
COV.00046	100 µg (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00046	100 µg (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00050	100 µg (18-55 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	01	Day 7	MA	36.8	None	None	None	Moderate	None	None
COV.00050	100 µg (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 2	MA	38.2 (Mild)	None	None	None	Mild	Moderate	Mild
COV.00050	100 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00050	100 µg (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
COV.00092	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	Mild	None	None
COV.00092	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
COV.00092	250 µg (18-55 years)	01	Day 1	MA	37.3	None	Moderate	Mild	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00092	250 µg (18-55 years)	01	Day 2	MA	37.3	None	Mild	Mild	None	None	None
COV.00092	250 µg (18-55 years)	01	Day 3	MA	37.1	None	Mild	Mild	Mild	Mild	None
COV.00092	250 µg (18-55 years)	01	Day 4	MA	37.3	None	Mild	None	Mild	Mild	None
COV.00092	250 µg (18-55 years)	01	Day 5	MA	37.3	None	Mild	None	Mild	Moderate	None
COV.00092	250 µg (18-55 years)	01	Day 6	MA	37.3	None	None	None	Mild	None	None
COV.00092	250 µg (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
COV.00092	250 µg (18-55 years)	01	Day 8	MA	37.4	None	None	None	Mild	None	None
COV.00092	250 µg (18-55 years)	01	Day 9	MA	N/A				Mild		
COV.00092	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00092	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00092	250 µg (18-55 years)	02	Day 1	MA	37.3	None	None	Mild	None	None	None
COV.00092	250 µg (18-55 years)	02	Day 2	MA	37.7	Mild	Moderate	Moderate	None	Mild	None
COV.00092	250 µg (18-55 years)	02	Day 3	MA	37.3	None	Mild	Mild	Mild	None	None
COV.00092	250 µg (18-55 years)	02	Day 4	MA	37.4	None	None	Mild	None	None	None
COV.00092	250 µg (18-55 years)	02	Day 5	MA	37.5	None	Moderate	None	None	None	None
COV.00092	250 µg (18-55 years)	02	Day 6	MA	37.5	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00092	250 µg (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
COV.00092	250 µg (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	Mild
COV.00091	250 µg (18-55 years)	01	Day 2	MA	36.4	None	Mild	None	None	None	Mild
COV.00091	250 µg (18-55 years)	01	Day 3	MA	36.5	None	Mild	Mild	None	None	None
COV.00091	250 µg (18-55 years)	01	Day 4	MA	36.6	None	Mild	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Day 5	MA	36.6	None	Mild	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Day 6	MA	36.6	None	Mild	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Day 1	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Moderate	Mild	Moderate
COV.00091	250 µg (18-55 years)	02	Day 2	MA	36.7	Moderate	Moderate	Moderate	Mild	Mild	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00091	250 µg (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	Mild	None
COV.00091	250 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Day 7	MA	36.5	None	None	None	None	None	None
COV.00091	250 µg (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00121	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 2	MA	36.7	None	None	Mild	None	Mild	None
COV.00121	100 µg (56-70 years)	02	Day 3	MA	37	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 7	MA	37	None	None	None	None	None	None
COV.00121	100 µg (56-70 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00119	100 µg (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	02	Day 1	MA	36.7	None	Mild	Mild	None	None	None
COV.00119	100 µg (56-70 years)	02	Day 2	MA	37.8	Mild	Moderate	Moderate	Mild	None	None
COV.00119	100 µg (56-70 years)	02	Day 3	MA	36.8	None	Mild	Mild	Mild	None	None
COV.00119	100 µg (56-70 years)	02	Day 4	MA	37.2	None	Mild	None	None	Mild	None
COV.00119	100 µg (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00119	100 µg (56-70 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00111	25 µg (56-70 years)	01	Day 1	MA	37.3	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00111	25 µg (56-70 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00111	25 µg (56-70 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	Mild	None
COV.00110	25 µg (56-70 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Day 2	MA	39.2 (Severe)	Moderate	Moderate	Moderate	Moderate	Moderate	Mild

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00110	25 µg (56-70 years)	02	Day 3	MA	38.2 (Mild)	None	None	None	None	Mild	None
COV.00110	25 µg (56-70 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Day 5	MA	37	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00110	25 µg (56-70 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 2	MA	36.7	None	None	None	Moderate	None	None
COV.00114	25 µg (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00114	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 1	MA	37.3	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 2	MA	36.9	None	None	None	None	Mild	None
COV.00114	25 µg (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00114	25 µg (56-70 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00116	25 µg (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 1	MA	37	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 2	MA	37.3	None	Mild	Mild	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 4	MA	37.2	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 7	MA	37	None	None	None	None	None	None
COV.00116	25 µg (56-70 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00123	100 µg (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 3	MA	37	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 4	MA	37.4	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Day 1	MA	37.3	Moderate	Mild	Moderate	Moderate	Moderate	Moderate
COV.00123	100 µg (56-70 years)	02	Day 2	MA	37.4	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
COV.00123	100 µg (56-70 years)	02	Day 3	MA	36.7	None	Mild	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Day 6	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00123	100 µg (56-70 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
COV.00123	100 µg (56-70 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 2	MA	36.7	None	None	Mild	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 2	MA	38.4 (Mild)	Mild	Mild	Mild	None	Mild	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00125	100 µg (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 5	MA	37	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00125	100 µg (56-70 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 3	MA	37	None	Mild	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00127	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
COV.00127	100 µg (56-70 years)	02	Day 2	MA	37.2	None	Mild	None	None	Mild	None
COV.00127	100 µg (56-70 years)	02	Day 3	MA	36.9	None	Mild	None	None	None	None
COV.00127	100 µg (56-70 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	02	Day 6	MA	36.7	Mild	None	None	None	None	Mild
COV.00127	100 µg (56-70 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00127	100 µg (56-70 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00115	25 µg (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 2	MA	36.9	None	Moderate	Mild	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 5	MA	36.9	Mild	Moderate	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 6	MA	36.8	None	Mild	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 7	MA	37	None	Mild	None	None	None	None
COV.00115	25 µg (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00138	100 µg (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 2	MA	37	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 4	MA	37	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
COV.00138	100 µg (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00215	50 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	Mild	None
COV.00215	50 µg (18-55 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00215	50 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	Mild	None	None
COV.00220	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	Mild	None	None
COV.00220	50 µg (18-55 years)	01	Day 1	MA	37.3	None	Mild	None	None	None	Moderate
COV.00220	50 µg (18-55 years)	01	Day 2	MA	36.8	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00220	50 µg (18-55 years)	01	Day 3	MA	37.2	None	Moderate	None	None	None	Moderate
COV.00220	50 µg (18-55 years)	01	Day 4	MA	36.8	None	Moderate	None	None	None	None
COV.00220	50 µg (18-55 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
COV.00220	50 µg (18-55 years)	01	Day 6	MA	36.9	None	Mild	None	None	None	None
COV.00220	50 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Day 1	MA	37.2	None	Moderate	None	None	None	Mild
COV.00220	50 µg (18-55 years)	02	Day 2	MA	38.2 (Mild)	None	Moderate	None	None	Severe	None
COV.00220	50 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00220	50 µg (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00234	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Day 2	MA	37.7	None	Moderate	Moderate	Moderate	Moderate	None
COV.00234	50 µg (18-55 years)	02	Day 3	MA	37.3	None	Moderate	Moderate	Moderate	Moderate	None
COV.00234	50 µg (18-55 years)	02	Day 4	MA	37.1	None	Mild	Mild	Mild	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00234	50 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
COV.00234	50 µg (18-55 years)	02	Day 8	MA	37.2	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00235	50 µg (18-55 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00235	50 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00047	100 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 1	MA	36.9	None	None	Mild	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 2	MA	37.4	None	Moderate	Mild	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00047	100 µg (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00048	100 µg (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 1	MA	36.7	None	Mild	Moderate	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	None	Mild	None
COV.00048	100 µg (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 6	MA	37	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00048	100 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00045	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 2	MA	37.5	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	Mild	None
COV.00045	100 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
COV.00045	100 µg (18-55 years)	02	Day 2	MA	37.8	Mild	Moderate	None	None	Mild	None
COV.00045	100 µg (18-55 years)	02	Day 3	MA	37	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00045	100 µg (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00045	100 µg (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	Mild	None	None
COV.00042	100 µg (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00042	100 µg (18-55 years)	02	Day 1	MA	37.7	Moderate	Moderate	Moderate	Moderate	Mild	Mild
COV.00042	100 µg (18-55 years)	02	Day 2	MA	37.2	Mild	Mild	Mild	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 8	MA	36.7	None	None	Mild	None	None	None
COV.00042	100 µg (18-55 years)	02	Day 12	MA	N/A			Mild			
COV.00056	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 2	MA	37.8	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 3	MA	37.7	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00056	100 µg (18-55 years)	01	Day 6	MA	37.4	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 1	MA	37	Mild	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 2	MA	37.3	Mild	Mild	None	None	None	Mild
COV.00056	100 µg (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 4	MA	36.1	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 6	MA	36.1	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 7	MA	36	None	None	None	None	None	None
COV.00056	100 µg (18-55 years)	02	Day 8	MA	35.8	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00093	250 µg (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	02	Day 1	MA	36.6	Moderate	None	None	None	Moderate	None
COV.00093	250 µg (18-55 years)	02	Day 2	MA	37.1	Moderate	Moderate	Mild	Mild	Moderate	None
COV.00093	250 µg (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
COV.00093	250 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00093	250 µg (18-55 years)	02	Day 7	MA	36.5	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00093	250 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	Mild	None
COV.00095	250 µg (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00095	250 µg (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00095	250 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	Mild	None
COV.00094	250 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
COV.00094	250 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
COV.00094	250 µg (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00094	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	02	Day 1	MA	36.7	Mild	None	Moderate	None	None	None
COV.00094	250 µg (18-55 years)	02	Day 2	MA	37.3	Mild	None	Mild	None	None	None
COV.00094	250 µg (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	Mild	None
COV.00094	250 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00094	250 µg (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	Mild	None
COV.00094	250 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	Mild	None
COV.00094	250 µg (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	Mild	None
COV.00106	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
COV.00106	25 µg (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
COV.00106	25 µg (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	01	Day 4	MA	36.6	None	None	None	Mild	Mild	None
COV.00106	25 µg (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00106	25 µg (56-70 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	01	Day 8	MA	36.4	None	None	None	Moderate	None	None
COV.00106	25 µg (56-70 years)	01	Day 10	MA	N/A				Mild		
COV.00106	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00106	25 µg (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00105	25 µg (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 6	MA	36.5	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 1	MA	36.7	None	None	Mild	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 2	MA	36.3	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00105	25 µg (56-70 years)	02	Day 7	MA	36.1	None	None	None	None	None	None
COV.00105	25 µg (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 1	MA	35.7	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 2	MA	36.1	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 4	MA	36.1	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 1	MA	36.4	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00124	100 µg (56-70 years)	02	Day 3	MA	35.8	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 4	MA	36	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 6	MA	35.7	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 7	MA	35.9	None	None	None	None	None	None
COV.00124	100 µg (56-70 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	01	Day 6	MA	36.7	None	Mild	Mild	Mild	None	None
COV.00113	25 µg (56-70 years)	01	Day 7	MA	36.4	None	None	Mild	Mild	None	None
COV.00113	25 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00113	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 2	MA	36.9	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 4	MA	36.2	None	None	None	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 5	MA	36.7	None	Mild	Mild	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 6	MA	36.4	None	Mild	Mild	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 7	MA	36.8	None	Mild	Mild	None	None	None
COV.00113	25 µg (56-70 years)	02	Day 8	MA	36.3	None	None	Mild	None	None	None
COV.00112	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00112	25 µg (56-70 years)	01	Day 5	MA	36.2	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 2	MA	36	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00112	25 µg (56-70 years)	02	Day 8	MA	36.2	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00118	100 µg (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	01	Day 8	MA	37	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Day 1	MA	36.2	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Day 2	MA	37.8	Moderate	Moderate	Moderate	None	None	Moderate
COV.00118	100 µg (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Day 6	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00118	100 µg (56-70 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00118	100 µg (56-70 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 2	MA	36.8	None	None	Mild	None	Mild	Mild

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00117	25 µg (56-70 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
COV.00117	25 µg (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 1	MA	36.2	None	Mild	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 4	MA	36.2	None	Mild	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	01	Day 8	MA	36.2	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00128	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Day 1	MA	37	None	Moderate	Mild	None	Mild	Mild
COV.00128	100 µg (56-70 years)	02	Day 2	MA	36.1	None	None	Mild	None	Mild	None
COV.00128	100 µg (56-70 years)	02	Day 3	MA	36.2	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00128	100 µg (56-70 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 2	MA	35.7	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 3	MA	35.5	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 4	MA	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00122	100 µg (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 6	MA	N/A	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 7	MA	35.4	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	01	Day 8	MA	35.3	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Day 1	MA	35.2	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Day 2	MA	37.3	None	Moderate	Moderate	None	Mild	None
COV.00122	100 µg (56-70 years)	02	Day 3	MA	35.6	None	Mild	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Day 4	MA	35.8	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Day 5	MA	35.6	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Day 6	MA	35.9	None	None	None	None	Mild	None
COV.00122	100 µg (56-70 years)	02	Day 7	MA	35.5	None	None	None	None	None	None
COV.00122	100 µg (56-70 years)	02	Day 8	MA	35.8	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00210	50 µg (18-55 years)	01	Day 1	MA	37.7	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Day 2	MA	37	None	Moderate	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	Mild	None
COV.00210	50 µg (18-55 years)	01	Day 4	MA	37.4	None	Mild	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Day 5	MA	36.9	None	Mild	Mild	Mild	None	None
COV.00210	50 µg (18-55 years)	01	Day 6	MA	37.5	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	02	Day 1	MA	36.7	None	Mild	Mild	None	None	None
COV.00210	50 µg (18-55 years)	02	Day 2	MA	37.6	Mild	Moderate	Moderate	Mild	Mild	Mild
COV.00210	50 µg (18-55 years)	02	Day 3	MA	37.1	None	Mild	Mild	None	Mild	None
COV.00210	50 µg (18-55 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00210	50 µg (18-55 years)	02	Day 7	MA	37	None	None	None	None	None	None
COV.00210	50 µg (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	Mild	None
COV.00223	50 µg (18-55 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 1	MA	37	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 2	MA	37.7	None	None	None	None	Mild	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00223	50 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
COV.00223	50 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 1	MA	37	None	Mild	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 2	MA	37.8	None	Mild	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 3	MA	37.6	None	Mild	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	01	Day 8	MA	36.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00239	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 1	MA	37.6	Mild	Moderate	None	None	Mild	None
COV.00239	50 µg (18-55 years)	02	Day 2	MA	37.1	None	Mild	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00239	50 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 4	MA	36.4	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00225	50 µg (18-55 years)	01	Day 5	MA	36.3	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 6	MA	36.1	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 1	MA	36.6	None	Mild	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 2	MA	36.2	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 4	MA	36.3	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00225	50 µg (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00008	25 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00008	25 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00008	25 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	Mild	None
COV.00009	25 µg (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	Mild	None
COV.00009	25 µg (18-55 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Day 2	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00009	25 µg (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Day 6	MA	37.4	None	None	None	None	None	None
COV.00009	25 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	Mild	None
COV.00009	25 µg (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00010	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00010	25 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Day 1	MA	37.5	None	Moderate	None	None	Mild	None
COV.00007	25 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	Mild	None
COV.00007	25 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00007	25 µg (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	Mild	None
COV.00007	25 µg (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00007	25 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00011	100 µg (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	02	Day 1	MA	37.7	Moderate	Mild	Moderate	None	Mild	Mild
COV.00011	100 µg (18-55 years)	02	Day 2	MA	37.2	None	Mild	Mild	None	Mild	Mild
COV.00011	100 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	Moderate	None
COV.00011	100 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
COV.00011	100 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00011	100 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00011	100 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	Mild	None
COV.00013	100 µg (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 6	MA	37.6	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Moderate	None	Mild	Mild
COV.00013	100 µg (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	None	Mild	None	None	Mild

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00013	100 µg (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
COV.00013	100 µg (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00030	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 1	MA	36.6	None	None	Mild	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 2	MA	37	None	Mild	Mild	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00030	25 µg (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00032	25 µg (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00032	25 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00012	100 µg (18-55 years)	01	Day 1	MA	37.6	Mild	Moderate	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 2	MA	37.2	Mild	Mild	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Day 1	MA	37.1	None	Mild	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	Mild	None	None	Moderate	Mild
COV.00012	100 µg (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00012	100 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00012	100 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
COV.00014	100 µg (18-55 years)	01	Day 1	MA	37	None	None	None	None	Mild	None
COV.00014	100 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 1	MA	37.4	Mild	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 2	MA	37.1	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00014	100 µg (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 5	MA	37.4	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
COV.00014	100 µg (18-55 years)	02	Day 8	MA	37.2	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00034	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 2	MA	37	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00034	25 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00031	25 µg (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00031	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00024	25 µg (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Day 2	MA	37.2	None	Mild	None	None	Moderate	Mild
COV.00024	25 µg (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00024	25 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00033	25 µg (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00033	25 µg (18-55 years)	02	Day 8	MA	N/A	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00028	25 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	Moderate	None	None
COV.00028	25 µg (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00028	25 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00025	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 1	MA	37.5	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 5	MA	37.4	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 6	MA	37	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 7	MA	37.5	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00025	25 µg (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 7	MA	37.6	None	None	None	None	None	None
COV.00025	25 µg (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 2	MA	36.8	None	Moderate	None	None	Mild	Moderate
COV.00027	25 µg (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00027	25 µg (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00078	250 µg (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	01	Day 8	MA	37.5	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	None	Mild	None	Mild	None
COV.00078	250 µg (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Day 5	MA	37.6	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00078	250 µg (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
COV.00078	250 µg (18-55 years)	02	Day 8	MA	N/A	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 2	MA	37.6	None	Moderate	Moderate	Moderate	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00026	25 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00026	25 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00029	25 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00029	25 µg (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
COV.00080	250 µg (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00080	250 µg (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Mild	None	None	None
COV.00080	250 µg (18-55 years)	02	Day 2	MA	38 (Mild)	Mild	None	None	Mild	Mild	None
COV.00080	250 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	Mild	Mild	None
COV.00080	250 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00080	250 µg (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00083	250 µg (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Day 1	MA	37.6	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Day 2	MA	37.5	None	Mild	Mild	None	Moderate	None
COV.00083	250 µg (18-55 years)	02	Day 3	MA	37.3	None	None	Mild	None	None	None
COV.00083	250 µg (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00083	250 µg (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
COV.00083	250 µg (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	Mild	None
COV.00079	250 µg (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
COV.00079	250 µg (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00081	250 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Day 1	MA	37.3	Severe	Mild	Mild	None	Mild	None
COV.00081	250 µg (18-55 years)	02	Day 2	MA	39.6 (Severe)	Severe	Severe	Moderate	Mild	Severe	Moderate
COV.00081	250 µg (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
COV.00081	250 µg (18-55 years)	02	Day 4	MA	36.8	None	Mild	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Day 5	MA	36.7	None	Mild	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Day 6	MA	37.1	None	Mild	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00081	250 µg (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00087	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	01	Day 1	MA	37.4	Mild	Mild	None	None	Moderate	None
COV.00087	250 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	Mild	None
COV.00087	250 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
COV.00087	250 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Day 1	MA	37.8	None	Mild	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Day 2	MA	38.8 (Moderate)	Severe	Severe	Moderate	Moderate	Moderate	Mild
COV.00087	250 µg (18-55 years)	02	Day 3	MA	36.8	None	Mild	None	None	Mild	None
COV.00087	250 µg (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00087	250 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Day 8	MA	36.7	None	Mild	None	None	None	None
COV.00087	250 µg (18-55 years)	02	Day 10	MA	N/A		Mild				
COV.00085	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 2	MA	37	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 5	MA	37.5	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00085	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	Mild	None
COV.00085	250 µg (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Severe	None	Severe	None	None	Severe
COV.00085	250 µg (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Day 4	MA	37.8	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00085	250 µg (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
COV.00086	250 µg (18-55 years)	01	Day 1	MA	36.8	None	Mild	Mild	None	Mild	None
COV.00086	250 µg (18-55 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	Moderate	None
COV.00086	250 µg (18-55 years)	01	Day 3	MA	36.7	None	Mild	None	None	Mild	None
COV.00086	250 µg (18-55 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00086	250 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	02	Day 1	MA	37.1	None	Moderate	Mild	None	Moderate	None
COV.00086	250 µg (18-55 years)	02	Day 2	MA	36.7	Mild	Moderate	Moderate	Moderate	Mild	None
COV.00086	250 µg (18-55 years)	02	Day 3	MA	36.7	None	Mild	Mild	None	None	None
COV.00086	250 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
COV.00086	250 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00086	250 µg (18-55 years)	02	Day 7	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
COV.00086	250 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Day 1	MA	37.3	Mild	Moderate	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00084	250 µg (18-55 years)	01	Day 2	MA	37.7	None	Mild	Mild	None	None	None
COV.00084	250 µg (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
COV.00084	250 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	02	Day 1	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	None	None
COV.00084	250 µg (18-55 years)	02	Day 2	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	Mild	None
COV.00084	250 µg (18-55 years)	02	Day 3	MA	37.2	None	Mild	None	None	None	None
COV.00084	250 µg (18-55 years)	02	Day 4	MA	37.1	None	Mild	None	None	None	None
COV.00084	250 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00084	250 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	Mild	None
COV.00084	250 µg (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00084	250 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 1	MA	36.6	None	Mild	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 4	MA	37.6	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	Mild	None
COV.00153	25 µg (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Day 1	MA	37	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Day 3	MA	36.4	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00153	25 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	Mild	None
COV.00153	25 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00153	25 µg (≥71 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00155	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00155	25 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 1	MA	36.2	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 5	MA	36.7	None	None	Mild	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00158	25 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 2	MA	36.6	None	None	Mild	None	Mild	None
COV.00158	25 µg (≥71 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00158	25 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	Mild	Mild	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00156	25 µg (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 4	MA	36.8	None	Mild	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 6	MA	36.8	None	Mild	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 1	MA	37.5	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 2	MA	36.9	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00156	25 µg (≥71 years)	02	Day 7	MA	37	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00156	25 µg (≥71 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 3	MA	37.2	None	None	Mild	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 4	MA	37.2	None	None	Mild	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 5	MA	37.3	None	None	Mild	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 6	MA	37.2	None	None	Mild	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 7	MA	36.9	None	None	Mild	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 8	MA	37.2	None	None	Mild	None	None	None
COV.00160	25 µg (≥71 years)	01	Day 14	MA	N/A			Mild			
COV.00160	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 1	MA	36.8	None	Mild	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 2	MA	37.2	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00160	25 µg (≥71 years)	02	Day 3	MA	37	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00160	25 µg (≥71 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 2	MA	36.5	None	Mild	Mild	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00184	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 2	MA	37.5	None	Mild	Mild	Mild	Mild	None
COV.00184	100 µg (≥71 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00184	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00157	25 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00157	25 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00154	25 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
COV.00154	25 µg (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00154	25 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00154	25 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 2	MA	37	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00169	100 µg (≥71 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00169	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00167	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 7	MA	35	None	None	None	None	None	None
COV.00167	25 µg (≥71 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00166	25 µg (≥71 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00166	25 µg (≥71 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00178	100 µg (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00178	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00178	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 6	MA	37	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 1	MA	37	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 2	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00159	25 µg (≥71 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00159	25 µg (≥71 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00168	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	02	Day 1	MA	38.1 (Mild)	Mild	Moderate	Mild	None	Moderate	Mild
COV.00168	100 µg (≥71 years)	02	Day 2	MA	37.8	None	Moderate	None	None	Moderate	None
COV.00168	100 µg (≥71 years)	02	Day 3	MA	37.1	None	None	None	None	Mild	None
COV.00168	100 µg (≥71 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00168	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00173	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 2	MA	37.4	Mild	Moderate	Moderate	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00173	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00176	100 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 2	MA	36.9	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 3	MA	37	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00176	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00176	100 µg (≥71 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 3	MA	36.8	None	Mild	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Day 2	MA	37.6	Moderate	Severe	Mild	None	Mild	None
COV.00186	100 µg (≥71 years)	02	Day 3	MA	36.7	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00186	100 µg (≥71 years)	02	Day 4	MA	37.1	None	Mild	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00186	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00172	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00172	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00177	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 2	MA	37.6	Mild	Moderate	Mild	None	Mild	None
COV.00177	100 µg (≥71 years)	02	Day 3	MA	36.8	None	None	Mild	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00177	100 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00174	100 µg (≥71 years)	01	Day 2	MA	36.7	Mild	Mild	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	02	Day 2	MA	37.4	None	Mild	Mild	Mild	None	None
COV.00174	100 µg (≥71 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	02	Day 4	MA	36.7	None	Mild	None	Mild	None	None
COV.00174	100 µg (≥71 years)	02	Day 5	MA	37.2	None	None	Mild	None	None	None
COV.00174	100 µg (≥71 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00174	100 µg (≥71 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00174	100 µg (≥71 years)	02	Day 8	MA	36.7	None	Mild	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Day 1	MA	36.8	None	Mild	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Day 2	MA	37.3	None	None	Mild	None	Mild	None
COV.00255	50 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00255	50 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00255	50 µg (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00254	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 2	MA	37.7	None	Moderate	Moderate	None	Moderate	None
COV.00254	50 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 7	MA	N/A	None	None	None	None	None	None
COV.00254	50 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00258	50 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 1	MA	36.7	Moderate	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 7	MA	37	None	None	None	None	None	None
COV.00258	50 µg (18-55 years)	02	Day 8	MA	36.2	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00256	50 µg (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Day 1	MA	37.1	None	Mild	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Day 2	MA	37.9	None	Mild	Mild	None	Mild	None
COV.00256	50 µg (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	Mild	None
COV.00256	50 µg (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00256	50 µg (18-55 years)	02	Day 7	MA	36.2	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00256	50 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
COV.00257	50 µg (18-55 years)	01	Day 2	MA	36.5	None	Moderate	None	None	Mild	None
COV.00257	50 µg (18-55 years)	01	Day 3	MA	36.6	None	Mild	None	None	Mild	None
COV.00257	50 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Day 2	MA	37.7	None	Moderate	Moderate	None	Moderate	None
COV.00257	50 µg (18-55 years)	02	Day 3	MA	36.7	None	Mild	Mild	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00257	50 µg (18-55 years)	02	Day 4	MA	36.5	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00257	50 µg (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 3	MA	37.4	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 5	MA	37.6	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00253	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 2	MA	37.1	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00253	50 µg (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00259	50 µg (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00259	50 µg (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 1	MA	36	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00240	50 µg (≥71 years)	01	Day 2	MA	36.5	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 3	MA	36.1	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 4	MA	36.2	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 5	MA	36.3	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 6	MA	36.2	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	01	Day 8	MA	36.2	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 1	MA	36.4	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 2	MA	35.9	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 3	MA	35.9	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 5	MA	36.2	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 6	MA	35.9	None	None	None	None	None	None
COV.00240	50 µg (≥71 years)	02	Day 7	MA	36.4	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00240	50 µg (≥71 years)	02	Day 8	MA	36.2	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 1	MA	36	None	None	None	None	Mild	None
COV.00208	50 µg (56-70 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 6	MA	35.8	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Day 1	MA	36.4	None	Mild	None	None	Mild	None
COV.00208	50 µg (56-70 years)	02	Day 2	MA	36.3	None	Mild	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Day 3	MA	36.4	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00208	50 µg (56-70 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Day 5	MA	36.2	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00208	50 µg (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 1	MA	36.1	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 7	MA	35.9	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00233	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 2	MA	37	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00233	50 µg (≥71 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 3	MA	36.1	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00221	50 µg (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 1	MA	36.4	None	Mild	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 2	MA	36.5	None	Mild	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 3	MA	36.4	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 4	MA	36.2	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 6	MA	36.3	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 7	MA	36.3	None	None	None	None	None	None
COV.00221	50 µg (56-70 years)	02	Day 8	MA	36.3	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 1	MA	36.9	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00207	50 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 6	MA	37	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 3	MA	36.2	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 6	MA	36.3	None	None	None	None	None	None
COV.00207	50 µg (56-70 years)	02	Day 7	MA	36.3	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00207	50 µg (56-70 years)	02	Day 8	MA	36.2	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 4	MA	36.2	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 3	MA	36.2	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00209	50 µg (56-70 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
COV.00209	50 µg (56-70 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 2	MA	36.9	None	None	Mild	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 3	MA	36.7	None	None	Mild	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 5	MA	37.2	None	None	None	None	None	Moderate
COV.00212	50 µg (56-70 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00212	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 7	MA	36.3	None	None	None	None	None	None
COV.00212	50 µg (56-70 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 5	MA	36.3	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00211	50 µg (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 2	MA	38.3 (Mild)	Mild	Mild	Mild	None	Mild	None
COV.00211	50 µg (56-70 years)	02	Day 3	MA	36.8	None	Mild	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 4	MA	36.2	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00211	50 µg (56-70 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00228	50 µg (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 1	MA	36.8	None	Mild	None	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 2	MA	37.3	None	Mild	Mild	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 3	MA	36.5	None	None	Mild	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 4	MA	36.8	None	None	Mild	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00228	50 µg (≥71 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00228	50 µg (≥71 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 2	MA	36.5	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 5	MA	36.3	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	01	Day 8	MA	36.2	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 1	MA	36.7	None	None	Mild	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 3	MA	36.5	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00224	50 µg (≥71 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 5	MA	36.2	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 6	MA	36.3	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 7	MA	36.2	None	None	None	None	None	None
COV.00224	50 µg (≥71 years)	02	Day 8	MA	36.3	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 5	MA	36.2	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 6	MA	36.5	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00213	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 2	MA	37.9	Moderate	Moderate	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 3	MA	36.6	None	Mild	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 4	MA	36.3	None	Moderate	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 5	MA	36.2	None	Mild	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 6	MA	36.4	None	Mild	None	None	Mild	None
COV.00213	50 µg (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00213	50 µg (56-70 years)	02	Day 8	MA	36.3	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00216	50 µg (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 4	MA	37	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 5	MA	37	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
COV.00216	50 µg (56-70 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00231	50 µg (≥71 years)	01	Day 2	MA	36.4	None	Mild	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 2	MA	36.3	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 3	MA	36.8	None	Moderate	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
COV.00231	50 µg (≥71 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00231	50 µg (≥71 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 6	MA	35.7	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	01	Day 8	MA	36.3	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 3	MA	36.1	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00241	50 µg (≥71 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
COV.00241	50 µg (≥71 years)	02	Day 8	MA	36.3	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 3	MA	36.4	None	Mild	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 4	MA	35.7	None	None	None	None	Mild	None
COV.00206	50 µg (≥71 years)	01	Day 5	MA	36.3	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 6	MA	37	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	01	Day 8	MA	36.3	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00206	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 2	MA	36.4	None	Mild	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
COV.00206	50 µg (≥71 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 4	MA	36	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00205	50 µg (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 6	MA	36.1	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
COV.00205	50 µg (56-70 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	Mild

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00222	50 µg (56-70 years)	01	Day 2	MA	36.5	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Day 1	MA	36.7	None	Mild	Mild	Mild	None	None
COV.00222	50 µg (56-70 years)	02	Day 2	MA	36.4	None	None	Mild	Mild	None	None
COV.00222	50 µg (56-70 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Day 4	MA	35.7	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
COV.00222	50 µg (56-70 years)	02	Day 7	MA	36.2	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00222	50 µg (56-70 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Day 1	MA	37.2	None	Moderate	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Day 2	MA	37.2	None	Mild	None	Mild	None	None
COV.00217	50 µg (≥71 years)	01	Day 3	MA	36.6	None	Mild	None	Mild	None	None
COV.00217	50 µg (≥71 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 2	MA	36.7	None	Mild	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 3	MA	36.4	None	Mild	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00217	50 µg (≥71 years)	02	Day 4	MA	36.9	None	Mild	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 5	MA	36.5	None	Mild	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 6	MA	37	None	Mild	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
COV.00217	50 µg (≥71 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	01	Day 8	MA	37	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00237	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 2	MA	36.9	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 5	MA	36.4	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 7	MA	37	None	None	None	None	None	None
COV.00237	50 µg (≥71 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 1	MA	36.2	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 4	MA	36.2	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
COV.00238	50 µg (≥71 years)	01	Day 6	MA	36.2	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 2	MA	37.6	None	Mild	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 3	MA	36.4	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
COV.00238	50 µg (≥71 years)	02	Day 8	MA	36.6	None	None	None	None	None	None

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.

Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**Listing 11:
Solicited Events – Local Symptoms**

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00090	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00090	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00090	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00044	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00044	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00043	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00043	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00051	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00051	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00049	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00049	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00049	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	Mild	0	1
COV.00046	100 µg (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	2
COV.00046	100 µg (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	2
COV.00046	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00046	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00046	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00050	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00050	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00092	250 µg (18-55 years)	01	Day 1	MA	Moderate	None	Moderate	0	75 (Moderate)
COV.00092	250 µg (18-55 years)	01	Day 2	MA	Mild	None	Moderate	0	78 (Moderate)
COV.00092	250 µg (18-55 years)	01	Day 3	MA	None	None	Mild	0	36 (Mild)
COV.00092	250 µg (18-55 years)	01	Day 4	MA	None	None	Mild	0	26 (Mild)
COV.00092	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	01	Day 7	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00092	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00092	250 µg (18-55 years)	02	Day 1	MA	Mild	None	Moderate	0	65 (Moderate)
COV.00092	250 µg (18-55 years)	02	Day 2	MA	Mild	None	Moderate	0	76 (Moderate)
COV.00092	250 µg (18-55 years)	02	Day 3	MA	Mild	None	Mild	0	23
COV.00092	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00092	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00091	250 µg (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00091	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00121	100 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00121	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00121	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00119	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00119	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 1	MA	Mild	None	Mild	0	35 (Mild)
COV.00111	25 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00111	25 µg (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	20

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00111	25 µg (56-70 years)	02	Day 2	MA	Mild	None	Mild	0	15
COV.00111	25 µg (56-70 years)	02	Day 3	MA	Mild	None	Mild	0	10
COV.00111	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00111	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00110	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00110	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00114	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00114	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00116	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00116	25 µg (56-70 years)	01	Day 1	MA	None	Mild	None	1	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00116	25 µg (56-70 years)	01	Day 2	MA	None	Mild	None	1	0
COV.00116	25 µg (56-70 years)	01	Day 3	MA	None	Mild	None	3	0
COV.00116	25 µg (56-70 years)	01	Day 4	MA	None	Mild	None	3	0
COV.00116	25 µg (56-70 years)	01	Day 5	MA	None	Mild	None	3	0
COV.00116	25 µg (56-70 years)	01	Day 6	MA	None	Mild	None	2	0
COV.00116	25 µg (56-70 years)	01	Day 7	MA	None	Mild	None	2	0
COV.00116	25 µg (56-70 years)	01	Day 8	MA	None	Mild	None	2	0
COV.00116	25 µg (56-70 years)	01	Day 10	MA	.	Mild	.	2	.
COV.00116	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00116	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00116	25 µg (56-70 years)	02	Day 2	MA	Mild	Mild	None	1	0
COV.00116	25 µg (56-70 years)	02	Day 3	MA	Mild	Mild	None	1	0
COV.00116	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00116	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00116	25 µg (56-70 years)	02	Day 6	MA	Mild	Mild	Mild	70 (Moderate)	70 (Moderate)

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00116	25 µg (56-70 years)	02	Day 7	MA	Mild	Mild	Mild	70 (Moderate)	70 (Moderate)
COV.00116	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	1
COV.00123	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	01	Day 2	MA	Mild	None	Mild	0	10
COV.00123	100 µg (56-70 years)	01	Day 3	MA	Mild	None	Mild	0	8
COV.00123	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00123	100 µg (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	3
COV.00123	100 µg (56-70 years)	02	Day 2	MA	Mild	None	Mild	0	2
COV.00123	100 µg (56-70 years)	02	Day 3	MA	None	None	Mild	0	2

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00123	100 µg (56-70 years)	02	Day 4	MA	None	None	Mild	0	2
COV.00123	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00123	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	3	0
COV.00125	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	02	Post-Dose	Clinic	None	Mild	None	2	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00125	100 µg (56-70 years)	02	Day 1	MA	None	Mild	None	2	0
COV.00125	100 µg (56-70 years)	02	Day 2	MA	Mild	Mild	None	3	0
COV.00125	100 µg (56-70 years)	02	Day 3	MA	Mild	Mild	None	3	0
COV.00125	100 µg (56-70 years)	02	Day 4	MA	None	Mild	None	3	0
COV.00125	100 µg (56-70 years)	02	Day 5	MA	None	Mild	None	2	0
COV.00125	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00125	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00127	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 2	MA	Mild	Mild	None	25 (Mild)	0
COV.00127	100 µg (56-70 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00127	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00115	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00115	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00138	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00138	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00215	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00215	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00220	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00220	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00234	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00234	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00234	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	02	Post-Dose	Clinic	None	Mild	None	2	0
COV.00235	50 µg (18-55 years)	02	Day 1	MA	None	Mild	None	1	0
COV.00235	50 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00235	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00235	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00047	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00047	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00048	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00048	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00045	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00045	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00042	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00042	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00042	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00056	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00056	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00093	250 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00093	250 µg (18-55 years)	02	Day 2	MA	None	Mild	None	65 (Moderate)	0
COV.00093	250 µg (18-55 years)	02	Day 3	MA	Mild	Mild	None	65 (Moderate)	0
COV.00093	250 µg (18-55 years)	02	Day 4	MA	Mild	Mild	None	40 (Mild)	0
COV.00093	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00093	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00095	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00095	250 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	02	Day 2	MA	Mild	Mild	None	40 (Mild)	0
COV.00095	250 µg (18-55 years)	02	Day 3	MA	Mild	Mild	None	50 (Moderate)	0
COV.00095	250 µg (18-55 years)	02	Day 4	MA	None	Mild	None	25 (Mild)	0
COV.00095	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00095	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00094	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00094	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00106	25 µg (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00106	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00106	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
COV.00105	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00105	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00105	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00124	100 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00124	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	Mild	0	15
COV.00113	25 µg (56-70 years)	01	Day 1	MA	None	None	Mild	0	20
COV.00113	25 µg (56-70 years)	01	Day 2	MA	None	None	Mild	0	5
COV.00113	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00113	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00113	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00112	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	Mild	0	1
COV.00112	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00112	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Post-Dose	Clinic	Mild	Mild	Mild	2	3

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00118	100 µg (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00118	100 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	02	Day 2	MA	Moderate	None	Moderate	0	50 (Moderate)
COV.00118	100 µg (56-70 years)	02	Day 3	MA	Mild	None	Mild	0	50 (Moderate)
COV.00118	100 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00118	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00118	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00117	25 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00117	25 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 2	MA	Mild	None	Mild	0	3
COV.00128	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00128	100 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00128	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00122	100 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00122	100 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00210	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 1	MA	Mild	Mild	None	1	0
COV.00210	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00210	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Post-Dose	Clinic	None	Mild	Mild	2	2

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00223	50 µg (18-55 years)	01	Day 1	MA	Mild	Mild	None	1	0
COV.00223	50 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Day 1	MA	Moderate	Mild	None	2	0
COV.00223	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00223	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00223	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00239	50 µg (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
COV.00239	50 µg (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	50 (Moderate)
COV.00239	50 µg (18-55 years)	01	Day 3	MA	Mild	None	Mild	0	50 (Moderate)
COV.00239	50 µg (18-55 years)	01	Day 4	MA	None	None	Mild	0	25 (Mild)
COV.00239	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00239	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00239	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00225	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00225	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00008	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00008	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00009	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00009	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00010	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00010	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00010	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00007	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00007	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00011	100 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00011	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00013	100 µg (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	2
COV.00013	100 µg (18-55 years)	01	Day 2	MA	Moderate	Mild	Mild	5	30 (Mild)
COV.00013	100 µg (18-55 years)	01	Day 3	MA	None	Mild	Mild	60 (Moderate)	45 (Mild)
COV.00013	100 µg (18-55 years)	01	Day 4	MA	Mild	None	None	0	0
COV.00013	100 µg (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
COV.00013	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00013	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 2	MA	Mild	Mild	None	35 (Mild)	0
COV.00013	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00013	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00030	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00030	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00032	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00032	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00032	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	01	Day 8	MA	None	Mild	Mild	40 (Mild)	40 (Mild)
COV.00012	100 µg (18-55 years)	01	Day 12	MA	.	Mild	Mild	110 (Severe)	40 (Mild)
COV.00012	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00012	100 µg (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
COV.00012	100 µg (18-55 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00012	100 µg (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	115 (Severe)	90 (Moderate)
COV.00012	100 µg (18-55 years)	02	Day 4	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
COV.00012	100 µg (18-55 years)	02	Day 5	MA	Mild	Mild	None	60 (Moderate)	0
COV.00012	100 µg (18-55 years)	02	Day 6	MA	None	Mild	None	60 (Moderate)	0
COV.00012	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00012	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00014	100 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00014	100 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00034	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00034	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00031	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00031	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00024	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00024	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00033	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00033	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00028	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00028	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00025	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00025	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00025	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00027	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00078	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 1	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00078	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00026	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00026	25 µg (18-55 years)	02	Day 1	MA	Mild	Mild	None	20	0
COV.00026	25 µg (18-55 years)	02	Day 2	MA	Moderate	Mild	None	20	0
COV.00026	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	02	Day 5	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00026	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00026	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00029	25 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00029	25 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	7
COV.00080	250 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00080	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00080	250 µg (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	30 (Mild)
COV.00080	250 µg (18-55 years)	02	Day 2	MA	Mild	None	Mild	0	20
COV.00080	250 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00080	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00083	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00083	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00079	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00079	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 2	MA	Moderate	None	Mild	0	30 (Mild)
COV.00081	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00081	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00081	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 4	MA	Mild	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00087	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00087	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00085	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00085	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00086	250 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00086	250 µg (18-55 years)	01	Day 1	MA	Moderate	None	Mild	0	1
COV.00086	250 µg (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	1
COV.00086	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00086	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00086	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00086	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00086	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00086	250 µg (18-55 years)	01	Day 8	MA	None	Mild	Mild	50 (Moderate)	50 (Moderate)
COV.00086	250 µg (18-55 years)	01	Day 12	MA	.	Mild	Mild	105 (Severe)	105 (Severe)
COV.00086	250 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00086	250 µg (18-55 years)	02	Day 1	MA	Moderate	Mild	Mild	10	60 (Moderate)
COV.00086	250 µg (18-55 years)	02	Day 2	MA	Moderate	Mild	Mild	75 (Moderate)	60 (Moderate)
COV.00086	250 µg (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	105 (Severe)	25 (Mild)
COV.00086	250 µg (18-55 years)	02	Day 4	MA	Mild	Mild	None	60 (Moderate)	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00086	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00086	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00086	250 µg (18-55 years)	02	Day 7	MA	Not Done	Not Done	Not Done	.	.
COV.00086	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 1	MA	Moderate	Mild	None	2	0
COV.00084	250 µg (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00084	250 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00084	250 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00153	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00153	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00155	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00155	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00158	25 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00158	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00158	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Day 1	MA	Mild	Mild	None	20	0
COV.00156	25 µg (≥71 years)	01	Day 2	MA	Mild	Mild	None	20	20
COV.00156	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00156	25 µg (≥71 years)	02	Day 1	MA	Mild	None	Mild	0	75 (Moderate)
COV.00156	25 µg (≥71 years)	02	Day 2	MA	None	None	Mild	0	.
COV.00156	25 µg (≥71 years)	02	Day 3	MA	None	Mild	None	90 (Moderate)	0
COV.00156	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00156	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00156	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00160	25 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00160	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00184	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00184	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00157	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00157	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00157	25 µg (≥71 years)	02	Day 2	MA	None	Mild	None	4	0
COV.00157	25 µg (≥71 years)	02	Day 3	MA	None	Mild	None	4	0
COV.00157	25 µg (≥71 years)	02	Day 4	MA	None	Mild	None	4	0
COV.00157	25 µg (≥71 years)	02	Day 5	MA	None	Mild	None	5	0
COV.00157	25 µg (≥71 years)	02	Day 6	MA	None	Mild	None	5	0
COV.00157	25 µg (≥71 years)	02	Day 7	MA	None	Mild	None	4	0
COV.00157	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00154	25 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00154	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00154	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00169	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00169	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00167	25 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00167	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00166	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
COV.00166	25 µg (≥71 years)	02	Day 3	MA	None	Mild	Mild	40 (Mild)	40 (Mild)
COV.00166	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00166	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00178	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00178	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00159	25 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00159	25 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00159	25 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Day 2	MA	Moderate	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Day 4	MA	None	Mild	None	.	0
COV.00168	100 µg (≥71 years)	02	Day 5	MA	None	Mild	None	.	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00168	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00168	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
COV.00173	100 µg (≥71 years)	02	Day 1	MA	Mild	None	Mild	0	70 (Moderate)
COV.00173	100 µg (≥71 years)	02	Day 2	MA	Mild	None	Mild	0	70 (Moderate)

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00173	100 µg (≥71 years)	02	Day 3	MA	Mild	None	Mild	0	60 (Moderate)
COV.00173	100 µg (≥71 years)	02	Day 4	MA	Mild	None	Mild	0	40 (Mild)
COV.00173	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00173	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00176	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00176	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00186	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	02	Post-Dose	Clinic	None	Mild	None	20	0
COV.00186	100 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	60 (Moderate)
COV.00186	100 µg (≥71 years)	02	Day 3	MA	None	Mild	None	60 (Moderate)	0
COV.00186	100 µg (≥71 years)	02	Day 4	MA	None	Mild	None	40 (Mild)	0
COV.00186	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00186	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00172	100 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 2	MA	Mild	None	Mild	0	50 (Moderate)
COV.00172	100 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00172	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00177	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Day 2	MA	Mild	Mild	None	2	0
COV.00177	100 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00177	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00177	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Day 2	MA	Mild	Mild	None	30 (Mild)	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00174	100 µg (≥71 years)	02	Day 3	MA	Mild	Mild	None	30 (Mild)	0
COV.00174	100 µg (≥71 years)	02	Day 4	MA	Mild	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00174	100 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00255	50 µg (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 2	MA	None	Mild	None	3	0
COV.00255	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00255	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00254	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00254	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00258	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00258	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00256	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00256	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00256	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 1	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 2	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 2	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00257	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00257	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	10
COV.00253	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00253	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00253	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 3	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 4	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00259	50 µg (18-55 years)	01	Day 6	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 7	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	01	Day 8	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 3	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 4	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 5	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 6	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 7	MA	None	None	None	0	0
COV.00259	50 µg (18-55 years)	02	Day 8	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00240	50 µg (≥71 years)	01	Day 1	MA	None	None	None	6	0
COV.00240	50 µg (≥71 years)	01	Day 2	MA	None	None	None	6	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00240	50 µg (≥71 years)	01	Day 3	MA	None	None	None	6	0
COV.00240	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00240	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00208	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00208	50 µg (56-70 years)	01	Day 1	MA	Mild	None	Moderate	0	55 (Moderate)
COV.00208	50 µg (56-70 years)	01	Day 2	MA	Mild	None	Mild	0	50 (Moderate)
COV.00208	50 µg (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00208	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00208	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00208	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00233	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00233	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00221	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00221	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00207	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00207	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00209	50 µg (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00209	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00212	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 3	MA	Mild	None	Moderate	0	80 (Moderate)
COV.00212	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00212	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00212	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00211	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00211	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00228	50 µg (≥71 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00228	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00224	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00224	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00213	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00213	50 µg (56-70 years)	02	Day 1	MA	Moderate	None	None	0	0
COV.00213	50 µg (56-70 years)	02	Day 2	MA	Moderate	Moderate	Moderate	95 (Moderate)	60 (Moderate)
COV.00213	50 µg (56-70 years)	02	Day 3	MA	Mild	Severe	Moderate	120 (Severe)	80 (Moderate)
COV.00213	50 µg (56-70 years)	02	Day 4	MA	Mild	Moderate	Moderate	85 (Moderate)	65 (Moderate)
COV.00213	50 µg (56-70 years)	02	Day 5	MA	None	None	Moderate	0	70 (Moderate)
COV.00213	50 µg (56-70 years)	02	Day 6	MA	None	None	Mild	0	40 (Mild)
COV.00213	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00213	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00216	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 1	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00216	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00216	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00231	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00231	50 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00231	50 µg (≥71 years)	01	Day 2	MA	None	None	None	3	10
COV.00231	50 µg (≥71 years)	01	Day 3	MA	None	None	None	5	20
COV.00231	50 µg (≥71 years)	01	Day 4	MA	None	None	Mild	9	25 (Mild)
COV.00231	50 µg (≥71 years)	01	Day 5	MA	None	None	Mild	7	35 (Mild)
COV.00231	50 µg (≥71 years)	01	Day 6	MA	Mild	None	Mild	15	25 (Mild)
COV.00231	50 µg (≥71 years)	01	Day 7	MA	None	None	None	10	20
COV.00231	50 µg (≥71 years)	01	Day 8	MA	None	None	Mild	20	32 (Mild)
COV.00231	50 µg (≥71 years)	01	Day 10	MA	.	.	Mild	20	32 (Mild)
COV.00231	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00231	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00231	50 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00231	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00231	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	10
COV.00231	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	20
COV.00231	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00231	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00231	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	Mild	0	17
COV.00241	50 µg (≥71 years)	01	Day 1	MA	Mild	Mild	Mild	4	3
COV.00241	50 µg (≥71 years)	01	Day 2	MA	Mild	Mild	Mild	4	3
COV.00241	50 µg (≥71 years)	01	Day 3	MA	Mild	Mild	Mild	3	2
COV.00241	50 µg (≥71 years)	01	Day 4	MA	Mild	Mild	Mild	2	1
COV.00241	50 µg (≥71 years)	01	Day 5	MA	Mild	None	Mild	0	1
COV.00241	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00241	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00241	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00206	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00206	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00205	50 µg (56-70 years)	01	Day 2	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00205	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00205	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 3	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 4	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 5	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 6	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 7	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	01	Day 8	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 2	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 3	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00222	50 µg (56-70 years)	02	Day 5	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 6	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 7	MA	None	None	None	0	0
COV.00222	50 µg (56-70 years)	02	Day 8	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00217	50 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00217	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 2	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00237	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 2	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 3	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00237	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 1	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 3	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 4	MA	None	None	None	0	0

Subject ID	Treatment Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
COV.00238	50 µg (≥71 years)	01	Day 5	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 6	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 7	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	01	Day 8	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Post-Dose	Clinic	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 1	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 2	MA	Mild	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 3	MA	Mild	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 4	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 5	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 6	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 7	MA	None	None	None	0	0
COV.00238	50 µg (≥71 years)	02	Day 8	MA	None	None	None	0	0

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.

Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**Listing 12:
Unsolicited Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00009, AE Number: 001									
Petechiae R Elbow	14 (8)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Petechiae
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00007, AE Number: 001									
Vomiting	0 (0)	Mild	Not related	Other: brushing tongue	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00007, AE Number: 002									
Shortness of Breath With Strenuous Activity	25 (17)	Mild	Not related	Other: Deconditioning	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00032, AE Number: 001									
Abdominal Gas	4 (0)	Mild	Not related	Other medical condition or illness: food intolerance	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Flatulence
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00032, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Systolic Hypertension	28 (8)	Mild	Not related	Other: Recent exertion	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00034, AE Number: 001									
Erythema	14 (14)	Mild	Not related	Study procedure: reaction to tape adhesive	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Erythema
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00031, AE Number: 001									
Sore Throat	1 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00031, AE Number: 002									
Sore Throat	15 (2)	Mild	Not related	Other: environmental	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00024, AE Number: 001									
Bruise at Blood Draw Site	8 (6)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00033, AE Number: 001									
Right Neck Strain	6 (2)	Mild	Not related	Other medical condition or illness: lifting weight	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00028, AE Number: 001									
Contact Dermatitis	3 (9)	Mild	Not related	Study procedure: tape adhesive reaction	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00028, AE Number: 002									
Cut On Right Index Finger	2 (2)	Mild	Not related	Other: accidental trauma	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin laceration
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00027, AE Number: 001									
Vomiting	1 (0)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00027, AE Number: 002									
Hives On Lower Extremities	5 (1)	Mild	Related	N/A	WD- Drug withdrawn	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Urticaria

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments: Has had episodes about once per year of hives in past, sometimes due to cat allergy and other times without known etiology. Denies noting relationship to particular activity but occurs when outdoors.									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00026, AE Number: 001									
Arm Weakness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscular weakness
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00026, AE Number: 002									
Bruise at Blood Draw Site	0 (8)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 01, Subject ID: COV.00026, AE Number: 003									
Bruise at Blood Draw Site	8 (3)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00009, AE Number: 002									
Left Palm Abrasion	5 (7)	Mild	Not related	Other: Trauma	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00009, AE Number: 003									
Jaw Pain	36 (61)	Mild	Not related	Other: eating large sandwiches	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Pain in jaw
Comments:									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00009, AE Number: 004									
Hordeolum Exacerbation	55 (Ongoing)	Moderate	Not related	Other medical condition or illness: hordeolum present prior to study; worsened	Not applicable	No		Infections and infestations	Hordeolum
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00010, AE Number: 001									
Infected Pustules	47 (42)	Mild	Not related	Other medical condition or illness: Bacterial infection	Not applicable	No	Recovered /resolved	Infections and infestations	Pustule
Comments: Telehealth visit 5June2020 for localized erythema and swelling of possible insect bite to L inner thigh.									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00030, AE Number: 001									
Vomiting	22 (1)	Moderate	Not related	Other medical condition or illness: Sinus Headache	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00030, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Fatigue	20 (3)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Fatigue
Comments: Had mild fatigue (in retrospect) for 2 days prior to onset of sinus headache. Seasonal allergies are asymptomatic now.									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00032, AE Number: 003									
Contusions	74 (12)	Mild	Not related	Other: altercation	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Contusion
Comments: involved in altercation where he was thrown to ground, striking L head and L shoulder									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00028, AE Number: 003									
Skin Irritation Encircling Injection Site	1 (8)	Mild	Not related	Study procedure: skin irritation from band aid	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site irritation
Comments: Reddened, puffy skin the size and shape of the dot bandaid place over the injection site. No reaction in the center of the circle.									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00028, AE Number: 004									
Bruises	14 (17)	Mild	Not related	Other: trauma from heavy weight	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Contusion
Comments: on forearms after moving furniture									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00028, AE Number: 005									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Presyncope	18 (0)	Mild	Not related	Other: Sudden postural change	Not applicable	No	Recovered /resolved	Nervous system disorders	Presyncope
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00026, AE Number: 004									
Bruise at Blood Draw Site	8 (7)	Mild	Not related	Study procedure: Venipuncture trauma	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00026, AE Number: 005									
Muscle Strain	11 (3)	Mild	Not related	Other: heavy lifting	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00026, AE Number: 006									
Bruise	25 (4)	Mild	Not related	Other: trauma from carrying load	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Contusion
Comments: 4 cm bruise on R shoulder									
Treatment Group: 25 µg (18-55 years), Dose #: 02, Subject ID: COV.00026, AE Number: 007									
Puncture Wound	72 (26)	Mild	Not related	Other: Foreign body	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Wound
Comments: Stepped on nail									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00220, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Stuffy Nose	3 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00220, AE Number: 002									
Bruising at Blood Draw Site	0 (10)	Mild	Not related	Study procedure: Phlebotomy	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00220, AE Number: 003									
Nasal Congestion	16 (2)	Moderate	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00220, AE Number: 004									
Skin Abrasion	16 (6)	Mild	Not related	Other: Trauma	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00234, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Abdominal Pain	17 (3)	Moderate	Not related	Other medical condition or illness: Ruptured Ovarian Cyst	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain
Comments: Had seen MD on 22Jun2020, an ultrasound was obtained that documented a ruptured ovarian cyst.									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00235, AE Number: 001									
Rash	21 (13)	Mild	Not related	Other medical condition or illness: Poison Ivy	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Rash
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00235, AE Number: 002									
Seasonal Allergies	17 (Ongoing)	Mild	Not related	Other: Environmental Exposure	Dose not changed	No	Recovering /resolving	Immune system disorders	Seasonal allergy
Comments: Itchy eyes, itchy throat									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00239, AE Number: 001									
Lymphadenopathy	0 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Blood and lymphatic system disorders	Lymphadenopathy
Comments: AE started after treatment administration on 05JUN2020.									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00258, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccinated Arm Weakness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vaccination site movement impairment
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00256, AE Number: 001									
Low Blood Sugar	13 (0)	Mild	Not related	Other: inadequate intake for activity	Dose not changed	No	Recovered /resolved	Investigations	Blood glucose decreased
Comments: nausea, lightheadedness									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00257, AE Number: 001									
Abrasions	24 (6)	Mild	Not related	Other: Bicycle fall	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00257, AE Number: 002									
Uri	20 (3)	Mild	Not related	Other: Viral illness	Dose not changed	No	Recovered /resolved	Infections and infestations	Upper respiratory tract infection
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00253, AE Number: 001									
Indigestion	4 (0)	Mild	Not related	Other: Food	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Dyspepsia
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 01, Subject ID: COV.00253, AE Number: 002									
Muscle Soreness	14 (1)	Mild	Not related	Other: overuse	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Myalgia

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00220, AE Number: 005									
Post Nasal Drip	1 (5)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Upper-airway cough syndrome
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00220, AE Number: 006									
Post Nasal Drip	14 (13)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Upper-airway cough syndrome
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00234, AE Number: 002									
Diarrhea	1 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Diarrhoea
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00234, AE Number: 003									
Sore Throat	20 (3)	Mild	Not related	Other medical condition or illness: Seasonal allergies	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00254, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Back Spasm	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle spasms
Comments: 7/15/2020 Subject woke at 2am on 7/14/20 after receiving second vaccine on 7/13/20. Her back has a spasm and then she continued to have body aches throughout the night. Took aspirin in the morning, did not work in the morning. Symptoms had resolved by midday and subject resumed normal activities.									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00254, AE Number: 002									
Vertigo	77 (0)	Mild	Not related	Other medical condition or illness: Cerumen impaction	Not applicable	No	Recovered /resolved	Ear and labyrinth disorders	Vertigo
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00256, AE Number: 002									
Exacerbation of Impacted Wisdom Teeth	2 (5)	Moderate	Not related	Other medical condition or illness: dental crowding	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Tooth impacted
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00256, AE Number: 003									
Bradycardia	9 (0)	Mild	Not related	Other: Physical conditioning	Not applicable	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00253, AE Number: 003									
Bradycardia	7 (7)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Cardiac disorders	Bradycardia

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Treatment Group: 50 µg (18-55 years), Dose #: 02, Subject ID: COV.00259, AE Number: 001									
Ecchymosis at Blood Draw Site	7 (19)	Mild	Not related	Study procedure: phlebotomy needle trauma	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site haemorrhage
Comments:									
Treatment Group: 50 µg (56-70 years), Dose #: 01, Subject ID: COV.00221, AE Number: 001									
Bradycardia	26 (0)	Mild	Not related	Other: distance runner	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments: Heart rate was 52 prior to vaccination and 56 about 1 hour after administration of the 2nd study vaccine.									
Treatment Group: 50 µg (56-70 years), Dose #: 01, Subject ID: COV.00212, AE Number: 001									
Gastrointestinal Discomfort	4 (0)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments: Complaint of nausea and lower abdominal cramping that resulted in interference with her usual activities. Symptoms resolved spontaneously within 3 hours.									
Treatment Group: 50 µg (56-70 years), Dose #: 01, Subject ID: COV.00216, AE Number: 001									
Muscle Strain	17 (11)	Mild	Not related	Other: injury	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: Strained left shoulder while opening her van									
Treatment Group: 50 µg (56-70 years), Dose #: 01, Subject ID: COV.00205, AE Number: 001									
Laceration	3 (9)	Mild	Not related	Other: Fall	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin laceration
Comments: laceration on forehead resulting from a fall									
Treatment Group: 50 µg (56-70 years), Dose #: 02, Subject ID: COV.00208, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Viral Syndrome	40 (27)	Severe	Not related	Other medical condition or illness: Viral syndrome most likely from community exposure	Not applicable	No	Recovered /resolved	Infections and infestations	Viral infection
Comments:									
Treatment Group: 50 µg (56-70 years), Dose #: 02, Subject ID: COV.00221, AE Number: 002									
Cracked tooth	80 (Ongoing)	Moderate	Not related	Other medical condition or illness: age-related	Not applicable	No	Recovering /resolving	Injury, poisoning and procedural complications	Tooth fracture
Comments:									
Treatment Group: 50 µg (56-70 years), Dose #: 02, Subject ID: COV.00207, AE Number: 001									
Bradycardia	0 (6)	Mild	Not related	Other: His pulse has a tendency to run low	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments: His pulse was 53 about 1 hour after vaccination.									
Treatment Group: 50 µg (56-70 years), Dose #: 02, Subject ID: COV.00222, AE Number: 001									
Urinary Tract Infection	31 (40)	Moderate	Not related	Other: bacterial infection	Not applicable	No	Recovered /resolved	Infections and infestations	Urinary tract infection
Comments:									
Treatment Group: 50 µg (≥71 years), Dose #: 01, Subject ID: COV.00240, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Traumatic Injuries	19 (21)	Mild	Not related	Other: Fall	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Injury
Comments: Xray exam normal on 24JUN2020									
Treatment Group: 50 µg (≥71 years), Dose #: 01, Subject ID: COV.00228, AE Number: 001									
Traumatic Injuries	20 (27)	Mild	Not related	Other: fell while running	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Injury
Comments: sustained abrasions to the right knee, right elbow and hands; mild right hip and buttock pain; mild pain on the right lateral chest wall									
Treatment Group: 50 µg (≥71 years), Dose #: 01, Subject ID: COV.00231, AE Number: 001									
Bruise at Injection Site	2 (30)	Mild	Not related	Study procedure: needle trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 50 µg (≥71 years), Dose #: 01, Subject ID: COV.00206, AE Number: 001									
Hypertension	0 (6)	Mild	Not related	Other: Distressed due to a family phone call	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments: blood pressure measured 60 minutes post administration									
Treatment Group: 50 µg (≥71 years), Dose #: 02, Subject ID: COV.00240, AE Number: 002									
Tick Bite	35 (22)	Mild	Not related	Other: Tick Bite	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Arthropod bite
Comments:									
Treatment Group: 50 µg (≥71 years), Dose #: 02, Subject ID: COV.00233, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Sore Throat	28 (1)	Mild	Not related	Other: dry air	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 50 µg (≥71 years), Dose #: 02, Subject ID: COV.00241, AE Number: 002									
Hypertension	0 (28)	Mild	Not related	Other medical condition or illness: Subject forgot to take blood pressure medications	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments: Elevated blood pressure prior to product administration.									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00044, AE Number: 001									
Elevated Heart Rate	13 (14)	Mild	Not related	Other: Caffeine ingestion	Dose not changed	No	Recovered /resolved	Investigations	Heart rate increased
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00051, AE Number: 001									
Sore Throat	4 (3)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00051, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Lower Back Muscle Strain	9 (6)	Moderate	Not related	Other: Exercise	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00049, AE Number: 001									
Bruise On Arm at Injection Site	6 (6)	Mild	Not related	Study procedure: Related to injection	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00046, AE Number: 001									
Burn On Wrist	14 (27)	Mild	Not related	Other: oven burn	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Thermal burn
Comments: 20 mm burn on left wrist from cooking									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00056, AE Number: 001									
Dizziness	1 (1)	Mild	Not related	Study procedure: phlebotomy and dehydration	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00011, AE Number: 001									
Bruise at Injection Site	1 (13)	Mild	Not related	Study procedure: trauma from needle	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00013, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vasodilation On Bilateral Hands	3 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Vascular disorders	Vasodilatation
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00013, AE Number: 002									
Injection Site Itching	2 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00012, AE Number: 001									
Bruise at Injection Site	0 (15)	Mild	Not related	Study procedure: Vaccine injection	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00012, AE Number: 002									
Decreased Appetite	0 (7)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00012, AE Number: 003									
Itching at Injection Site	7 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00014, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Nasal Congestion	1 (0)	Mild	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 01, Subject ID: COV.00014, AE Number: 002									
R Breast Pain	20 (4)	Mild	Not related	Other: Premenstrual	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Breast pain
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00049, AE Number: 002									
Bradycardia	14 (12)	Mild	Not related	Other: Conditioned athlete	Not applicable	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00046, AE Number: 002									
Gastroenteritis	78 (1)	Moderate	Not related	Other medical condition or illness: Alcohol ingestion and fatty food ingestion	Not applicable	No	Recovered /resolved	Infections and infestations	Gastroenteritis
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00046, AE Number: 003									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Worsening Adhd Symptoms	21 (61)	Moderate	Not related	Other medical condition or illness: ADHD	Not applicable	No	Recovered /resolved	Psychiatric disorders	Attention deficit hyperactivity disorder
Comments: Problems with concentration, trouble learning and paying attention to her online classes.									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00050, AE Number: 001									
Infected Cyst	61 (9)	Moderate	Not related	Other medical condition or illness: Bacterial Infection	Not applicable	No	Recovered /resolved	Infections and infestations	Infected cyst
Comments: Underwent incision and drainage with purulence. Administered antibiotics									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00047, AE Number: 001									
Abdominal Cramping	0 (1)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00011, AE Number: 002									
Neck Pain	2 (1)	Mild	Not related	Other: Positional stress	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Neck pain
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00011, AE Number: 003									
Back Muscle Strain	22 (48)	Mild	Not related	Other: positional	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00013, AE Number: 003									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Diaphragmatic Cramping	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Diaphragmatic spasm
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00012, AE Number: 004									
Decreased Appetite	0 (3)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00012, AE Number: 005									
Feeling of Restlessness	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Feeling jittery
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00012, AE Number: 006									
Eye Irritation	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Eye disorders	Eye irritation
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00012, AE Number: 007									
Stomach Upset	4 (0)	Mild	Not related	Other: dietary intolerance	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00012, AE Number: 008									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Itching at Injection Site	3 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Treatment Group: 100 µg (18-55 years), Dose #: 02, Subject ID: COV.00012, AE Number: 009									
Dark Stools	4 (11)	Mild	Not related	Other: Dietary change	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Faeces discoloured
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00090, AE Number: 001									
Headache	10 (0)	Moderate	Not related	Other medical condition or illness: has a baseline history of Headache	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00090, AE Number: 002									
Headache	27 (0)	Moderate	Not related	Other medical condition or illness: Tension Headaches	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00092, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Decreased Appetite	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00092, AE Number: 002									
Worsening Vaginal Itching	6 (34)	Mild	Not related	Other medical condition or illness: Vaginal Itching	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Vulvovaginal pruritus
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00092, AE Number: 003									
Headache	8 (12)	Mild	Not related	Other: stress	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00092, AE Number: 004									
Lip Bumps	21 (7)	Mild	Not related	Other medical condition or illness: dermatitis	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Lip disorder
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00091, AE Number: 001									
Redness at Vaccine Site	12 (3)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: Subject seen today for routine follow up visit. First noted it on 27APR2020. Size was 92mm.									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00093, AE Number: 001									
Hypertension	6 (0)	Mild	Not related	Study procedure: Failed to repeat blood pressure measurement	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00079, AE Number: 001									
Right Knee Pain	2 (0)	Mild	Not related	Other: inactivity	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Arthralgia
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00079, AE Number: 002									
Sore Throat	24 (3)	Mild	Not related	Other medical condition or illness: Viral illness	WD- Drug withdrawn	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00079, AE Number: 003									
Vaginal Itching	56 (18)	Mild	Not related	Other medical condition or illness: Fungal infection	Not applicable	No	Recovered /resolved	Reproductive system and breast disorders	Vulvovaginal pruritus
Comments:									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00079, AE Number: 004									
Anal Fissure	56 (21)	Mild	Not related	Other: mechanical pressure from stool	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Anal fissure
Comments: See in UC for perianal pain. Dx with anal fissure. Prescribed lidocaine 2% gel. Improving as of 6/23/2020.									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00079, AE Number: 005									
Uti	133 (2)	Mild	Not related	Other medical condition or illness: bacterial infection	Not applicable	No	Recovered /resolved	Infections and infestations	Urinary tract infection
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00081, AE Number: 001									
Injection Site Redness	10 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00087, AE Number: 001									
Vaginal Spotting	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Vaginal haemorrhage
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00086, AE Number: 001									
Itching at Injection Site	7 (4)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00086, AE Number: 002									
Bradycardia	14 (14)	Mild	Not related	Other: physical conditionin g	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00086, AE Number: 005									
Hypotension Systolic	28 (15)	Mild	Not related	Other: Decreased activity level	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypotension
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 01, Subject ID: COV.00084, AE Number: 001									
Muscle Strain In Neck	11 (7)	Moderate	Not related	Other: sleeping position	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle strain
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00090, AE Number: 003									
Headache	23 (0)	Moderate	Not related	Other medical condition or illness: Headache medical history	Not applicable	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00091, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Abdominal Discomfort	26 (10)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00093, AE Number: 002									
Hypoglycemia	7 (7)	Moderate	Not related	Other: decreased PO intake	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Hypoglycaemia
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00080, AE Number: 001									
Stomach Ache	7 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain upper
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00083, AE Number: 002									
Muscle Spasms	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle spasms
Comments: in neck and back, spasms cycled over minutes between clench and release.									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00083, AE Number: 003									
Loss of Appetite	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00081, AE Number: 002									
Vomiting	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00081, AE Number: 003									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Lightheadedness	1 (0)	Severe	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00081, AE Number: 004									
Syncope	1 (0)	Severe	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Syncope
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00081, AE Number: 005									
Bruise at Phlebotomy Site R Arm	1 (16)	Mild	Not related	Other: trauma from blood draw	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: This was from blood draw at urgent care visit, not a study visit, per query.									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00081, AE Number: 006									
Recurrence of Scintillating Scotomata	13 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Eye disorders	Scintillating scotoma
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00081, AE Number: 007									
Epididymitis	29 (16)	Moderate	Not related	Other medical condition or illness: Bacterial infection	Not applicable	No	Recovered /resolved	Infections and infestations	Epididymitis
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00087, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Loss of Appetite	0 (2)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00087, AE Number: 003									
Sweating	0 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Hyperhidrosis
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00087, AE Number: 004									
Insomnia	7 (Ongoing)	Mild	Not related	Other: situational stress	Not applicable	No		Psychiatric disorders	Insomnia
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00087, AE Number: 005									
Anxiety	1 (11)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Psychiatric disorders	Anxiety
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00087, AE Number: 006									
Hand Ache	8 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Pain in extremity
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00086, AE Number: 003									
Malaise	1 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Malaise

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00086, AE Number: 004									
Night Sweats	2 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00086, AE Number: 006									
Bradycardia	15 (15)	Mild	Not related	Other: Physical conditionin g	Not applicable	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Treatment Group: 250 µg (18-55 years), Dose #: 02, Subject ID: COV.00086, AE Number: 007									
Indigestion	14 (13)	Mild	Not related	Other: Dietary changes	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Dyspepsia
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00111, AE Number: 001									
Headache	27 (0)	Mild	Not related	Other medical condition or illness: tension headaches	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00111, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Worsening toenail Fungus	25 (Ongoing)	Moderate	Not related	Other medical condition or illness: Fungal infection	Dose not changed	No	Recovering /resolving	Infections and infestations	Onychomycosis
Comments: Subject went to MD on 28JUL2020. Updated form to MAAE.									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00114, AE Number: 001									
Worsening of Sciatica	5 (1)	Mild	Not related	Other: Exercise paddle boating	Dose not changed	No	Recovered /resolved	Nervous system disorders	Sciatica
Comments: Subject has pre-existing sciatica pain that occurs occasionally. Subject mentioned worsening of sciatica following paddle boating.									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00114, AE Number: 002									
Exposure to Inhaled Irritants	12 (0)	Moderate	Not related	Other: exposure to onions	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Exposure via inhalation
Comments: Subject went onion picking and developed tearing and rhinorrhea. She took Benadryl with resolution of her symptoms.									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00116, AE Number: 001									
Sore Throat	1 (1)	Mild	Not related	Other medical condition or illness: SEASONAL ALLERGIES	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: She has seasonal allergies at part of her past medical history. Her sore throat felt similar to prior seasonal allergy issues that she has had due to high pollen count.									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00115, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Bruise at Injection Site	1 (11)	Mild	Not related	Study procedure: Vaccine Administration	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 01, Subject ID: COV.00113, AE Number: 001									
Bruise at Injection Site	0 (4)	Mild	Not related	Study procedure: vaccination procedure	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 02, Subject ID: COV.00110, AE Number: 001									
No Appetite	1 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: Combined solicited systemic Symptoms kept subject from eating for > 24 hours.									
Treatment Group: 25 µg (56-70 years), Dose #: 02, Subject ID: COV.00114, AE Number: 003									
Worsening of Sciatica	56 (39)	Moderate	Not related	Other medical condition or illness: Activity	Not applicable	No	Recovered /resolved	Nervous system disorders	Sciatica
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 02, Subject ID: COV.00114, AE Number: 004									
Decreased Bone Density	28 (Ongoing)	Moderate	Not related	Other medical condition or illness: Aging	Not applicable	No	Recovering /resolving	Investigations	Bone density decreased

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 02, Subject ID: COV.00116, AE Number: 002									
Trauma to Arm	6 (16)	Moderate	Not related	Other: cat attack	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Limb injury
Comments: Bruise and cat scratches on L arm by her own cat which suffers from dementia.									
Treatment Group: 25 µg (56-70 years), Dose #: 02, Subject ID: COV.00105, AE Number: 001									
Insomnia	0 (1)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Psychiatric disorders	Insomnia
Comments:									
Treatment Group: 25 µg (56-70 years), Dose #: 02, Subject ID: COV.00113, AE Number: 002									
Foot Pain	6 (Ongoing)	Mild	Not related	Other medical condition or illness: plantar fasciitis	Not applicable	No	Not recovered /Not resolved	Musculoskeletal and connective tissue disorders	Pain in extremity
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00123, AE Number: 001									
Nasal Congestion	13 (2)	Moderate	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: took pseudoephedrine once, currently much improved minimal residual symptoms									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00127, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Sore Throat	21 (1)	Mild	Not related	Other: Environmental Exposure	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00138, AE Number: 001									
Paronychia	2 (13)	Moderate	Not related	Other medical condition or illness: Bacterial Infection	Dose not changed	No	Recovered /resolved	Infections and infestations	Paronychia
Comments: Redness & Swelling that developed 25APR2020. This worsened on 26APR2020 and she presented to Urgent Care where she had an incision and drainage performed under local anesthetics (Lidocaine). She was given a dose of Ceftriaxone and discharged on Sulfamethoxazole-Trimethoprim.									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00138, AE Number: 002									
Maculopapular Rash	9 (21)	Moderate	Not related	Other drug: Sulfamethoxazole-Trimethoprim	WD- Drug withdrawn	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Rash maculo-papular
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00138, AE Number: 003									
Contact Dermatitis	111 (26)	Moderate	Not related	Other: Poison Ivy	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00118, AE Number: 001									
Systolic Hypertension	14 (15)	Mild	Not related	Other: labile blood pressure	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 01, Subject ID: COV.00122, AE Number: 001									
Hypoglycemia	8 (5)	Severe	Not related	Other: fasting and vigorous exercise	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Hypoglycaemia
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 02, Subject ID: COV.00121, AE Number: 001									
Hemorrhoids	4 (5)	Mild	Not related	Other medical condition or illness: hemorrhoids	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Haemorrhoids
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 02, Subject ID: COV.00119, AE Number: 001									
Bee Sting Skin Reaction	27 (4)	Mild	Not related	Other: Bee sting	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Arthropod sting
Comments: 1.5 x 1.5 red area on right forehead Red facial bump									
Treatment Group: 100 µg (56-70 years), Dose #: 02, Subject ID: COV.00128, AE Number: 001									
Vertigo	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Ear and labyrinth disorders	Vertigo
Comments:									
Treatment Group: 100 µg (56-70 years), Dose #: 02, Subject ID: COV.00128, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Dizziness	5 (0)	Mild	Not related	Other: strenuous exercise and dehydration	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00153, AE Number: 001									
Sunburn	4 (9)	Mild	Not related	Other: Excessive sun exposure	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Sunburn
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00153, AE Number: 002									
Pustule	20 (35)	Mild	Not related	Other medical condition or illness: Bacterial infection	Dose not changed	No	Recovered /resolved	Infections and infestations	Pustule
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00155, AE Number: 001									
Bilateral Ankle Swelling	2 (1)	Mild	Not related	Other: Wore a constrictive pair of new socks	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Joint swelling
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00155, AE Number: 004									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Burn L Forearm	28 (35)	Mild	Not related	Other medical condition or illness: Thermal trauma	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Thermal burn
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00158, AE Number: 001									
Lightheadedness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00158, AE Number: 002									
Night Sweats	2 (2)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00158, AE Number: 003									
Anxiety	4 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Psychiatric disorders	Anxiety
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00156, AE Number: 001									
Increased Energy	0 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Energy increased
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00156, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Lightheadedness	28 (0)	Mild	Not related	Study procedure: Blood draw	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00160, AE Number: 001									
L Upper torso Musculoskeletal Pain	1 (12)	Moderate	Not related	Other: Bicycle accident	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00160, AE Number: 002									
Abrasion to L Elbow	1 (14)	Mild	Not related	Other: Bicycle accident	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00154, AE Number: 001									
Itching Lateral R Clavicle	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Pruritus
Comments: 5-10 minute duration									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00167, AE Number: 001									
L Upper Arm Abrasion	0 (10)	Mild	Not related	Other: Scratched arm while doing yardwork	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00167, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Bruise at Injection Site	2 (10)	Mild	Not related	Study procedure: Needle trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00167, AE Number: 003									
Tick Bite	3 (85)	Mild	Not related	Other: Insect bite	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Arthropod bite
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00167, AE Number: 004									
Exacerbation of Arthritis	27 (62)	Moderate	Not related	Other: overuse	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Arthritis
Comments: Pts states has had for 2 yrs and increased and decreased with activity. Much worse than previous events, started wearing brace (from MD sister). 6/10/20 Subject states condition remains. Has phone visit with provider on 6/11/20 6/16/20 MAAE as of 6/12/20 - video appointment with occupational therapy									
Treatment Group: 25 µg (≥71 years), Dose #: 01, Subject ID: COV.00159, AE Number: 001									
Disturbed Sleep Cycle	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Psychiatric disorders	Sleep disorder
Comments: At V7 phone call, subject reported sleep cycle disturbance after first vaccine but had not previously reported.									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00153, AE Number: 003									
Fingertip Puncture	10 (8)	Mild	Not related	Other: Trauma	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Limb injury
Comments: <5 mm puncture wound to R 5th fingertip.									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00155, AE Number: 005									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Excoriation	8 (1)	Mild	Not related	Other: Scratching where adhesive bandage was placed	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00156, AE Number: 003									
Increased Energy	0 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Energy increased
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00156, AE Number: 004									
Decreased Peripheral Vision	0 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Visual field defect
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00156, AE Number: 005									
Itching at Injection Site	2 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00156, AE Number: 006									
Fatigue	11 (13)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Fatigue
Comments:									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00160, AE Number: 003									
Skin Irritation	0 (0)	Mild	Not related	Other: irritation from shirt fabric	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Skin irritation
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00157, AE Number: 001									
Left Triceps Tightness	1 (2)	Mild	Not related	Other: Muscle overuse	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle tightness
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00157, AE Number: 002									
Post Operative Pain	16 (10)	Mild	Not related	Other: scheduled hernia surgery	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Procedural pain
Comments: Elective umbilical hernia repair on 06/17/2020, outpatient. Previously scheduled to be done prior to enrollment and delayed due to pandemic. No change in severity or nature of the hernia between enrollment and procedure to repair.									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00159, AE Number: 002									
Disturbed Sleep Cycle	1 (1)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Psychiatric disorders	Sleep disorder
Comments:									
Treatment Group: 25 µg (≥71 years), Dose #: 02, Subject ID: COV.00159, AE Number: 003									
Bradycardia	28 (56)	Mild	Not related	Other: physical conditionin g	Not applicable	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 01, Subject ID: COV.00169, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Dermatitis	0 (10)	Mild	Not related	Other: Reaction to adhesive on tape	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 01, Subject ID: COV.00178, AE Number: 001									
Bruise at Injection Site	0 (17)	Mild	Not related	Study procedure: Needle trauma from vaccine	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 01, Subject ID: COV.00178, AE Number: 002									
Bruise at Blood Draw Site	0 (9)	Mild	Not related	Study procedure: Needle trauma from phlebotomy	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 01, Subject ID: COV.00178, AE Number: 003									
Bruise at Blood Draw Site	27 (78)	Mild	Not related	Study procedure: phlebotomy trauma from needle	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 01, Subject ID: COV.00186, AE Number: 001									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Erythema Distal And Medial to Injection Site	9 (7)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: 50 mm faint erythema present at V5									
Treatment Group: 100 µg (≥71 years), Dose #: 01, Subject ID: COV.00172, AE Number: 001									
Bruise at Blood Draw Site	3 (1)	Mild	Not related	Study procedure: Needle trauma from phlebotomy	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00184, AE Number: 001									
Systolic Hypertension	14 (14)	Mild	Not related	Other: strenuous exercise prior to visit	Not applicable	No	Recovered /resolved	Vascular disorders	Systolic hypertension
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00184, AE Number: 002									
Muscle Soreness	27 (0)	Mild	Not related	Other: overuse	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Myalgia
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00169, AE Number: 002									
Chipped tooth	3 (76)	Mild	Not related	Other: Weakened enamel	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Tooth fracture
Comments:									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00169, AE Number: 003									
Blister	2 (2)	Mild	Not related	Other: long periods of time exercising	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Blister
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00169, AE Number: 004									
Bruise at Blood Draw Site	7 (16)	Mild	Not related	Study procedure: Phlebotomy needle trauma	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: 6/30/ Bruise resolved per subject on 6/25/20									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00169, AE Number: 005									
Left Knee Bruise	15 (14)	Mild	Not related	Other: trauma	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Contusion
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00169, AE Number: 006									
Right Knee Abrasion	23 (14)	Mild	Not related	Other: fall	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00169, AE Number: 007									
Right Forearm Bruise	23 (14)	Mild	Not related	Other: fall	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Contusion
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00178, AE Number: 004									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Abrasions	27 (2)	Mild	Not related	Other: trauma from thorns	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00168, AE Number: 001									
Dizziness	0 (1)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00168, AE Number: 002									
Bruise	0 (9)	Mild	Not related	Study procedure: Blood draw	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Contusion
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00168, AE Number: 003									
Skin Rash	11 (2)	Mild	Not related	Other: use of over the counter cosmetic cream	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Rash
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00186, AE Number: 002									
Uti	58 (3)	Mild	Not related	Other medical condition or illness: infection	Not applicable	No	Recovered /resolved	Infections and infestations	Urinary tract infection
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00172, AE Number: 002									

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Bradycardia	29 (Ongoing)	Mild	Not related	Other: physical conditionin g	Not applicable	No		Cardiac disorders	Bradycardia
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00177, AE Number: 001									
Irritant Contact Dermatitis	0 (22)	Mild	Not related	Other drug: Efudex	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00177, AE Number: 002									
Abrasion	13 (9)	Mild	Not related	Other: trauma	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00177, AE Number: 003									
Squamous Cell Carcinoma	79 (0)	Mild	Not related	Other: Cell growth	Not applicable	No	Recovered /resolved	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma
Comments:									
Treatment Group: 100 µg (≥71 years), Dose #: 02, Subject ID: COV.00174, AE Number: 001									
Night Sweats	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									